Preclinical Imaging Market Share, Growth, Opportunities 2031
Preclinical Imaging Market Share, Growth, Opportunities 2031
Segments - Preclinical Imaging Market by Modality (Micro-MRI, Micro-CT, Micro-ultrasound, Nuclear Imaging Systems, Optical Imaging Systems, Photoacoustic Imaging Systems, and Others), Application (Drug Discovery and Research & Development), End-user (Research Institutes, Pharmaceutical Companies, and Biotechnology Companies), Reagent (PET Tracers, Contrast Agents, Optical Imaging Reagents, and SPECT Probes), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
Upcoming
| Report ID :HC-1234
| 4.6 Rating
| 68 Reviews
| 187 Pages
| Format :
Report Description
The global preclinical imaging market size was around USD 866.56 Mn in 2022 and is likely to reach USD 1352.4 Mn by 2031, expanding at a CAGR of 5.08% during 2023–2031. The market growth is attributed to the technological advancement in molecular imaging, the rising number of pharmaceutical companies & clinical research organizations, and a growing number of pre-clinical imaging systems in vivo research.
Preclinical imaging is the visualization of living animals for research purposes. Imaging modalities are used to observe changes in cells, organs, molecular level, and tissue in animals responding to environmental and psychological changes. Small animal models are used in basic and preclinical sciences and are the main keystone for research and development strategies.
Preclinical imaging techniques help in decreasing biological variability and the opportunity to acquire a large amount of information. Preclinical imaging helps to understand the underlying mechanism of diseases, and provides unique and efficient tools for the evaluation of new chemical entities and candidate drugs.
Multimodal molecular imaging plays an important role in the clinical care of different diseases by improving clinicians’ ability to perform staging, screening, planning and therapy guidance, surveillance, prognosis, assessing reassurance, and monitoring therapy efficacy.
The research report finds that the COVID-19 pandemic negatively impacted several industries and the lifestyle of people. Coronavirus disease shut down economics, closed borders, and spread misery on a global scale. However, the pandemic has positive impact on hospitals and clinics, as it increases the hospital capacity for patients diagnosed with coronavirus disease.
The pandemic had a considerable influence on the preclinical imaging market, due to the rising preclinical research studies and activities to test the safety and efficacy of clinical trials. Various companies, researchers, and the government boosted the demand for clinical trials and preclinical imaging devices. Moreover, immunomodulators, anticoagulants, antivirals, and other medicines are in high demand, as they act as a roadmap to prioritize compounds for clinical testing.
In April 2020, the National Institutes of Health announced the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership, to promote a coordinated research strategy and to develop promising treatments and vaccines.
Preclinical Imaging Market Dynamics
Major Drivers
Rising funding for supporting preclinical research is anticipated to boost market growth during the forecast period. Growing demand for non-invasive animal imaging techniques is projected to propel the market expansion in the coming years. Moreover, the rapid growth of the research and development sector is a major factor spurring market growth.
Existing Restraints
Rising adoption of computerized research models, lesser research developments, and strict rules and regulations imposed by the government, which protect animal rights are major factors hampering the market growth. Furthermore, high implementation cost in preclinical imaging and a lack of skilled research personnel is expected to hamper the market in the coming years.
Emerging Opportunities
R&D investment and technological advancement in the preclinical imaging market are projected to offer immense opportunities for the market players. Growing demand for non-invasive small animal imaging techniques is expected to create lucrative opportunities in the coming years.
Scope of Preclinical Imaging Market Report
The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Preclinical Imaging Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2022 |
|
Historic Data |
2016–2021 |
|
Forecast Period |
2023–2031 |
|
Segmentation |
Modality (Micro-MRI, Micro-CT, Micro-ultrasound, Nuclear Imaging Systems, Optical Imaging Systems, Photoacoustic Imaging Systems, and Others), Application (Drug Discovery and Research & Development), End-user (Research Institutes, Pharmaceutical Companies, and Biotechnology Companies), and Reagent (PET Tracers, Contrast Agents, Optical Imaging Reagents, and SPECT Probes) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Agilent Technologies, Inc.; Bruker Corporation; MILabs B.V.; Siemens; Medico Ltd.; General Electric; VisualSonics, Inc.; PerkinElmer, Inc.; and TriFoil Imaging |
Preclinical Imaging Market Segment Insights
Modality Segment Analysis
On the basis of modality, the market is segmented into micro-MRI, micro-CT, micro-ultrasound, nuclear imaging systems, optical imaging systems, photoacoustic imaging systems, and others. The micro-ultrasound segment is projected to expand at a considerable CAGR during the forecast period, due to the high usage of micro-ultrasound imaging systems in preclinical research studies around the world.
Micro-ultrasound is important for imaging modality for research and studies in developmental biology, cardiovascular diseases, and cancer. It is highly used for assessing placental, maternal, morphology, and hemodynamics, as well as for image-guided teratology and utero interventions.
Micro-ultrasound helps to study the normal development and models of human diseases in small animals. It helps the researcher to know the physiological, cellular, and molecular changes in animals and to anticipate the outcome of different new treatments in patients.
The nuclear imaging systems segment is anticipated to account for a major market share during the forecast period. Nuclear imaging systems are used to administrate a small amount of radioactivity in the human body. It produces a pictorial representation of metabolic processes by detecting radiation from various parts of the body.
Application Segment Analysis
Based on application, the preclinical imaging market is divided into drug discovery and research & development. The drug discovery segment is expected to hold a significant share of the market in the coming years. In drug discovery, preclinical trials are conducted by researchers in vitro and in vivo with unrestricted dosages.
Preclinical imaging is used to identify new druggable targets, evaluate biodistribution and appropriate dosing strategies, test efficacy and off-targets, and select appropriate patient cohorts for initial testing.
The research & development segment accounts for a significant market share, as preclinical imaging aids in phenotyping, drug discovery, and in providing a basic understanding of the mechanism of diseases. Preclinical imaging aid in observing changes, at the cell, tissue, organ, or molecular level as animals respond to physiological or environmental changes.
End-User Segment Analysis
On the basis of end-user, the global market is segregated into research institutes, pharmaceutical companies, and biotechnology companies. The research institutes segment is anticipated to expand at a substantial CAGR during the forecast period. Preclinical imaging is a strategic technology. It is used to support preclinical research and biopharmaceutical development.
The biotechnology companies segment is expected to hold a significant share of the market. Preclinical imaging is a useful method in research and it involves animals to find out effective procedures, drugs, or treatments. Biotechnology companies test new drugs on animals, before testing on human beings. This is the important stage of the development of new drugs.
Reagent Segment Analysis
Based on reagent, the market is segmented into PET tracers, contrast agents, optical imaging reagents, and SPECT probes. The PET tracers segment is projected to register a considerable share of the market in the coming years.
PET radiotracer is a position-emitting radiopharmaceutical (PET) that is generally used in positron emission tomography. A common radiotracer is F-18 fluorodeoxyglucose (FDG), a molecule similar to glucose. This radiotracer consists of a positron-emitting isotope bound to an organic ligand.
The optical imaging reagents segment is expected to hold a substantial CAGR. Optical imaging reagents are important for the diagnosis and monitoring of oncological, cardiovascular, neurological, and numerous other types of disease. Optical imaging reagents are forms of gallium, fluorine, technetium, xenon, galium, indium, and iodine for use with SPECT.
Regional Analysis
In terms of regions, the global preclinical imaging market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the forecast period, owing to a well-established player, rising funding to support preclinical research, technological advancements in the field of molecular imaging, and rising market demand for non-invasive small animal imaging techniques.
The market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period, due to less stringent regulatory guidelines, low research costs, and increased government funding for the development of the research sector in the respective countries. Moreover, the preclinical research outsourcing industry is growing in developing countries including India and China.
Segments
The global preclinical imaging market has been segmented on the basis of
Modality
- Micro-MRI
- Micro-CT
- Micro-ultrasound
- Nuclear Imaging Systems
- Optical Imaging Systems
- Photoacoustic Imaging Systems
- Others
Application
- Drug Discovery
- Research & Development
End-user
- Research Institutes
- Pharmaceutical Companies
- Biotechnology Companies
Reagent
- PET Tracers
- Contrast Agents
- Optical Imaging Reagents
- SPECT Probes
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Agilent Technologies, Inc.
- Bruker Corporation
- MILabs B.V.
- Siemens
- Medico Ltd.
- General Electric
- VisualSonics, Inc.
- PerkinElmer, Inc.
- TriFoil Imaging
Competitive Landscape
Key players competing in the global preclinical imaging market are Agilent Technologies, Inc.; Bruker Corporation; MILabs B.V.; Siemens; Medico Ltd.; General Electric; VisualSonics, Inc.; PerkinElmer, Inc.; and TriFoil Imaging.
Some of the major companies in the market have adopted various organic growth strategies including product launches, mergers, partnerships, and collaborations to increase their market share and witness significant growth. Key players are actively engaged in R&D programs and aim at the expansion of manufacturing units to expand their consumer base and increase their product portfolio.
- In October 2020, MR Solutions a leading company based in UK, received a purchase order for their preclinical devices of up to USD 10 million from top universities. PET/CTs, PET/MRs, and 9.4T and 7T cryogen-free DRY magnets were the top sellers, among market players.
- In May 2022, Bruker launched innovative 7 Tesla and 9.4 Tesla conduction-cooled Maxwell magnets for its market-leading preclinical magnetic resonance imaging (MRI) systems portfolio.
- In April 2022, PerkinElmer announced the expansion of its in vivo imaging portfolio with the launch of the Vega imaging system, a first-of-its-kind ultrasound platform that combines hands-free, automated technology with the high-throughput capability to accelerate non-invasive research and drug development studies of cancer, liver and kidney disease, cardiology and more.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Preclinical Imaging Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Preclinical Imaging Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Preclinical Imaging Market - Supply Chain
4.5. Global Preclinical Imaging Market Forecast
4.5.1. Preclinical Imaging Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Preclinical Imaging Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Preclinical Imaging Market Absolute $ Opportunity
5. Global Preclinical Imaging Market Analysis and Forecast by Applications
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Applications
5.2.2. Y-o-Y Growth Projections by Applications
5.3. Preclinical Imaging Market Size and Volume Forecast by Applications
5.3.1. Drug Discovery
5.3.2. Research & Development
5.4. Absolute $ Opportunity Assessment by Applications
5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Preclinical Imaging Market Analysis and Forecast by End Users
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by End Users
6.2.2. Y-o-Y Growth Projections by End Users
6.3. Preclinical Imaging Market Size and Volume Forecast by End Users
6.3.1. Research Institutes
6.3.2. Pharmaceutical Companies
6.3.3. Biotechnology Companies
6.4. Absolute $ Opportunity Assessment by End Users
6.5. Market Attractiveness/Growth Potential Analysis by End Users
7. Global Preclinical Imaging Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. Preclinical Imaging Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global Preclinical Imaging Demand Share Forecast, 2019-2026
8. North America Preclinical Imaging Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America Preclinical Imaging Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America Preclinical Imaging Market Size and Volume Forecast by Applications
8.4.1. Drug Discovery
8.4.2. Research & Development
8.5. Basis Point Share (BPS) Analysis by Applications
8.6. Y-o-Y Growth Projections by Applications
8.7. North America Preclinical Imaging Market Size and Volume Forecast by End Users
8.7.1. Research Institutes
8.7.2. Pharmaceutical Companies
8.7.3. Biotechnology Companies
8.8. Basis Point Share (BPS) Analysis by End Users
8.9. Y-o-Y Growth Projections by End Users
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America Preclinical Imaging Demand Share Forecast, 2019-2026
9. Latin America Preclinical Imaging Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America Preclinical Imaging Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America Preclinical Imaging Market Size and Volume Forecast by Applications
9.4.1. Drug Discovery
9.4.2. Research & Development
9.5. Basis Point Share (BPS) Analysis by Applications
9.6. Y-o-Y Growth Projections by Applications
9.7. Latin America Preclinical Imaging Market Size and Volume Forecast by End Users
9.7.1. Research Institutes
9.7.2. Pharmaceutical Companies
9.7.3. Biotechnology Companies
9.8. Basis Point Share (BPS) Analysis by End Users
9.9. Y-o-Y Growth Projections by End Users
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America Preclinical Imaging Demand Share Forecast, 2019-2026
10. Europe Preclinical Imaging Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe Preclinical Imaging Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe Preclinical Imaging Market Size and Volume Forecast by Applications
10.4.1. Drug Discovery
10.4.2. Research & Development
10.5. Basis Point Share (BPS) Analysis by Applications
10.6. Y-o-Y Growth Projections by Applications
10.7. Europe Preclinical Imaging Market Size and Volume Forecast by End Users
10.7.1. Research Institutes
10.7.2. Pharmaceutical Companies
10.7.3. Biotechnology Companies
10.8. Basis Point Share (BPS) Analysis by End Users
10.9. Y-o-Y Growth Projections by End Users
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe Preclinical Imaging Demand Share Forecast, 2019-2026
11. Asia Pacific Preclinical Imaging Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific Preclinical Imaging Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific Preclinical Imaging Market Size and Volume Forecast by Applications
11.4.1. Drug Discovery
11.4.2. Research & Development
11.5. Basis Point Share (BPS) Analysis by Applications
11.6. Y-o-Y Growth Projections by Applications
11.7. Asia Pacific Preclinical Imaging Market Size and Volume Forecast by End Users
11.7.1. Research Institutes
11.7.2. Pharmaceutical Companies
11.7.3. Biotechnology Companies
11.8. Basis Point Share (BPS) Analysis by End Users
11.9. Y-o-Y Growth Projections by End Users
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific Preclinical Imaging Demand Share Forecast, 2019-2026
12. Middle East & Africa Preclinical Imaging Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa Preclinical Imaging Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa Preclinical Imaging Market Size and Volume Forecast by Applications
12.4.1. Drug Discovery
12.4.2. Research & Development
12.5. Basis Point Share (BPS) Analysis by Applications
12.6. Y-o-Y Growth Projections by Applications
12.7. Middle East & Africa Preclinical Imaging Market Size and Volume Forecast by End Users
12.7.1. Research Institutes
12.7.2. Pharmaceutical Companies
12.7.3. Biotechnology Companies
12.8. Basis Point Share (BPS) Analysis by End Users
12.9. Y-o-Y Growth Projections by End Users
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa Preclinical Imaging Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global Preclinical Imaging Market: Market Share Analysis
13.2. Preclinical Imaging Distributors and Customers
13.3. Preclinical Imaging Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
13.4.1. Agilent Technologies, Inc.
13.4.2. Bruker Corporation
13.4.3. MILabs B.V.
13.4.4. Siemens
13.4.5. Medico Ltd.
13.4.6. General Electric
13.4.7. VisualSonics, Inc.
13.4.8. PerkinElmer, Inc.
13.4.9. TriFoil Imaging
Methodology
Related Reports
Some other reports from this category!
Our Clients
